ABC | Volume 112, Nº5, May 2019

Original Article Oliveira et al Stents for diabetic patients – VICTIM Register Arq Bras Cardiol. 2019; 112(5):564-570 This is an open-access article distributed under the terms of the Creative Commons Attribution License 14. de Waha A, Dibra A, Byrne RA, Ndrepepa G, Mehilli J, Fusaro M, et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2011;4(4):371-7. 15. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with baremetal stents. N Engl J Med. 2007;356(3):1030-9. 16. Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database of Syst Rev. 2010;(5):CD004587 17. Jimenez-Quevedo P, SabateM, AngiolilloDJ, Alfonso F, Hernández-Antolín R, SanMartín M, et al. Long-term clinical benefits of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: longterm results of the DIABETES trial. Eur Heart J. 2007; 28(16):1946-52. 18. Baumgart D, Klauss V, Baer F , Hartmann F, Drexler H, Motz W. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol. 2007;50(17):1627-34. 19. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J,et al. Sirolimu-seluting stent or paclitaxel-eluting stent versus balloon angioplasty for prevention of recurrences in patients with coronary instent restenosis: a randomized controlled trial. JAMA. 2005;293(2):165-71. 570